Andrew Reardon insider trades: Ligand Pharmaceuticals (LGND) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $313.22 | $1.6M | Direct | Nov 4, 2026 (2d) |
| Oct 2, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $304.07 | $1.5M | Direct | Oct 6, 2026 (4d) |
| Sep 3, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $286.09 | $1.4M | Direct | Sep 8, 2026 (5d) |
| Aug 3, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $288.99 | $1.4M | Direct | Aug 4, 2026 (1d) |
| Jul 1, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $313.28 | $1.6M | Direct | Jul 6, 2026 (5d) |
| Jun 1, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $227.06 | $1.1M | Direct | Jun 2, 2026 (1d) |
| May 1, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $231.31 | $1.2M | Direct | May 4, 2026 (3d) |
| Apr 1, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $201.24 | $1.0M | Direct | Apr 2, 2026 (1d) |
| Mar 4, 2026 | LGND | ↓ Sell10b5-1 | 5,000 | $206.35 | $1.0M | Direct | Mar 6, 2026 (2d) |
| Jun 23, 2025 | LGND | ↓ Sell | 500 | $114.08 | $57K | Direct | Jun 24, 2025 (1d) |
| Jun 10, 2025 | LGND | ↓ Sell | 500 | $114.54 | $57K | Direct | Jun 12, 2025 (2d) |
| May 15, 2025 | LGND | ↓ Sell | 1,000 | $104.00 | $104K | Direct | Jun 2, 2025 (18d) |
| Sep 23, 2024 | LGND | ↓ Sell | 2,000 | $99.60 | $199K | Direct | Sep 25, 2024 (2d) |
| Aug 28, 2024 | LGND | ↓ Sell | 1,500 | $106.39 | $160K | Direct | Aug 30, 2024 (2d) |
| May 9, 2024 | LGND | ↓ Sell | 10,000 | $83.04 | $830K | Direct | May 13, 2024 (4d) |
| Mar 24, 2023 | LGND | ↓ Sell | 300 | $69.92 | $21K | Direct | Mar 28, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LGND insiders
Open-market trades in the last 12 months
About Andrew Reardon's insider trades
Andrew Reardon is CLO & Secretary at Ligand Pharmaceuticals (LGND). Since Mar 24, 2023, Andrew has reported no open-market purchases and 16 sales worth $13.3M on SEC Form 4. In the last 12 months: 9 sales ($11.9M).
9 sales (89% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (11 filings), shares withheld for taxes (7 filings), grants and awards (5 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LGND insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.